128 related articles for article (PubMed ID: 38374579)
1. Selenium supplementation in inactive moderate to severe Graves' orbitopathy patients: a randomized controlled trial.
Potita P; Pruksakorn V; Srichomkwun P; Kingpetch K; Saonanon P
Orbit; 2024 Jun; 43(3):329-336. PubMed ID: 38374579
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.
Wang C; Qiao J; Liu S; Piao S; Zhou Y; Hu Y; Wan C; Sun Y; Ning H; Chen L; Zhang H; Hu R; Wang H; Wang W; Zhao L; Mao J; Li M; Teng W; Shan Z; Li Y
Endocrine; 2024 Jun; 84(3):1072-1080. PubMed ID: 38200401
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of selenium supplementation for mild-to-moderate Graves' ophthalmopathy in a selenium-sufficient area (SeGOSS trial): study protocol for a phase III, multicenter, open-label, randomized, controlled intervention trial.
Chung CW; Jung KY; Jung EH; Lee MJ; Park YJ; Lee JK; Ahn HY; Cho SW
Trials; 2023 Apr; 24(1):272. PubMed ID: 37060084
[TBL] [Abstract][Full Text] [Related]
5. Oral selenium improved the disease activity in patients with mild Graves' orbitopathy.
Almanza-Monterrubio M; Garnica-Hayashi L; Dávila-Camargo A; Nava-Castañeda Á
J Fr Ophtalmol; 2021 May; 44(5):643-651. PubMed ID: 33863564
[TBL] [Abstract][Full Text] [Related]
6. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
Trials; 2013 Apr; 14():119. PubMed ID: 23782950
[TBL] [Abstract][Full Text] [Related]
7. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin F2-Alpha Eye Drops (Bimatoprost) in Graves' Orbitopathy: A Randomized Controlled Double-Masked Crossover Trial (BIMA Trial).
Draman MS; Morris DS; Evans S; Haridas A; Pell J; Greenwood R; Foy C; Taylor P; Pooprasert P; Muller I; Zhang L; Lane C; Okosieme O; Ludgate M; Dayan C
Thyroid; 2019 Apr; 29(4):563-572. PubMed ID: 30880626
[TBL] [Abstract][Full Text] [Related]
9. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.
Bednarczuk T; Schomburg L
Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
11. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
12. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
13. Serum selenium status in Egyptians patients who had Graves' disease with and without ophthalmopathy.
Hasanin GA; Mohamed MS; Maher MM; Ahmed AM; ALi HM; Mansour HK
Egypt J Immunol; 2024 Jan; 31(1):133-142. PubMed ID: 38224470
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for thyroid-associated ophthalmopathy.
Kang S; Hamed Azzam S; Minakaran N; Ezra DG
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009226. PubMed ID: 35709102
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]